These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19690476)

  • 21. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
    Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
    Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
    Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy.
    Mukku RB; Fonarow GC; Watson KE; Ajijola OA; Depasquale EC; Nsair A; Baas AS; Deng MC; Yang EH
    J Card Fail; 2016 Jun; 22(6):439-48. PubMed ID: 27109619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
    Jahangir E; Shah S; Shum K; Baxter C; Fitzpatrick JD; Cole J; Gilliland Y; Polin NM
    South Med J; 2015 Feb; 108(2):71-8. PubMed ID: 25688890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthracycline-induced cardiomyopathy.
    Keefe DL
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracycline cardiotoxicity in children.
    Kremer LC; Caron HN
    N Engl J Med; 2004 Jul; 351(2):120-1. PubMed ID: 15247351
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.